CAR T cells in multiple myeloma: lessons learned.
Vinay Prasad
Author Information
- Vinay Prasad: Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. vinayak.prasad@ucsf.edu. ORCID
No abstract text available.
- US Food and Drug Administration. March 15, 2024: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. fda.gov, https://www.fda.gov/advisory-committees/advisory-committee-calendar/march-15-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-03152024 (accessed 19 March 2024).
- Sokolic, R. Oncologic Drugs Advisory Committee Meeting Introductory Comments. Ciltacabtagene Autoleucel. fda.org, https://www.fda.gov/media/177057/download (2024).
- Sokolic, R. Oncologic Drugs Advisory Committee Meeting Introductory Comments. Idecabtagene Vicleucel (ide-cel). fda.gov, https://www.fda.gov/media/177060/download (2024).
- Olivier, T., Haslam, A. & Prasad, V. Reporting of physicians��� or investigators��� choice of treatment in oncology randomized clinical trials. JAMA Netw. Open 5, e2144770 (2022).
[DOI: 10.1001/jamanetworkopen.2021.44770]
- ODAC. March 15, 2024 Oncologic Drugs Advisory Committe Meeting. fdazoomgov.com, https://go.nature.com/4baYsLo (2024).
- Olivier, T., Haslam, A. & Prasad, V. Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020. BMC Cancer 23, 448 (2023).
[DOI: 10.1186/s12885-023-10917-z]
- Mohyuddin, G. R. et al. Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: a systematic review and meta-analysis. Eur. J. Cancer 156, 164���174 (2021).
[DOI: 10.1016/j.ejca.2021.07.036]
- Hernandez, I., Prasad, V. & Gellad, W. F. Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol. 4, 994���996 (2018).
[DOI: 10.1001/jamaoncol.2018.0977]
- Centers for Medicare & Medicaid Services. National Coverage Determination. Chimeric Antigen Receptor (CAR) T-cell therapy. 110.24. cms.gov, https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=374 (accessed 22 April 2024).
- Centers for Medicare & Medicaid Services. National Coverage Determination Process & Timeline. cms.gov, https://www.cms.gov/cms-guide-medical-technology-companies-and-other-interested-parties/coverage/national-coverage-determination-process-timeline (accessed 19 March 2024).
Multiple Myeloma
Humans
Immunotherapy, Adoptive
Receptors, Chimeric Antigen
T-Lymphocytes
Receptors, Chimeric Antigen
